All Phenotypes Nkx3-1<+> MGI Mouse

About Help FAQ

Phenotypes associated with this allele

Allele Symbol
Allele Name
Allele ID

Nkx3-1⁺
wild type
MGI:2153462

Summary

7 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
ht1	Nkx3-1^tm1Mms/Nkx3-1⁺	either: (involves: 129S1/Sv * 129S1/SvImJ) or (involves: 129S1/Sv * 129S1/SvImJ * C57BL/6J)	MGI:2175153
ht2	Nkx3-1^tm1Hha/Nkx3-1⁺	involves: 129S4/SvJae * C57BL/6	MGI:2175151
ht3	Nkx3-1^tm2Mms/Nkx3-1⁺	involves: 129S6/SvEvTac * C57BL/6	MGI:3719105
cn4	Braf^tm1Mmcm/Braf^tm1Mmcm Nkx3-1^{tm4(cre/ERT2)Mms}/Nkx3-1⁺ Pten^tm1Hwu/Pten⁺	involves: 129P2/OlaHsd * 129S4/SvJae * 129S6/SvEvTac * C57BL/6	MGI:5543907
cn5	Nkx3-1^{tm4(cre/ERT2)Mms}/Nkx3-1⁺ Pten^tm1Hwu/Pten^tm1Hwu	involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6	MGI:4365721
cn6	Klf6^tm1Fjs/Klf6^tm1Fjs Nkx3-1^tm3(cre)Mms/Nkx3-1⁺	involves: 129/Sv * C57BL/6	MGI:4361338
cx7	Nkx3-1^tm1Mms/Nkx3-1⁺ Pten^tm1Rps/Pten⁺	involves: 129S1/Sv * 129S1/SvImJ * C57BL/6J	MGI:5569928

Allelic Composition	Nkx3-1^tm1Mms/Nkx3-1⁺
Genetic Background	either: (involves: 129S1/Sv * 129S1/SvImJ) or (involves: 129S1/Sv * 129S1/SvImJ * C57BL/6J)

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Nkx3-1^tm1Mms mutation (0 available); any Nkx3-1 mutation (34 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

endocrine/exocrine glands

prostate gland anterior lobe hyperplasia ( J:54465 )

• at 1 year, the anterior prostate of heterozygotes exhibits epithelial hyperplasia of reduced severity relative to homozygotes

abnormal prostate gland epithelium morphology ( J:54465 )

• at 1 year, the anterior prostate of heterozygotes exhibits epithelial dysplasia of reduced severity relative to homozygotes

• in addition, heterozygous dorsolateral prostates display a mild dysplasia relative to wild-type

prostate gland epithelial hyperplasia ( J:54465 )

• adult heterozygotes exhibit progressive prostate epithelial hyperplasia of reduced severity relative to homozygotes

abnormal prostate gland physiology ( J:54465 )

• at 6 weeks, heterozygotes exhibit a 4.5-fold increase in epithelial cell proliferation in the anterior prostate relative to wild-type mice

• adult heterozygotes show a significant reduction or loss of major secretory proteins in ventral prostate secretions

reproductive system

prostate gland anterior lobe hyperplasia ( J:54465 )

• at 1 year, the anterior prostate of heterozygotes exhibits epithelial hyperplasia of reduced severity relative to homozygotes

abnormal prostate gland epithelium morphology ( J:54465 )

• at 1 year, the anterior prostate of heterozygotes exhibits epithelial dysplasia of reduced severity relative to homozygotes

• in addition, heterozygous dorsolateral prostates display a mild dysplasia relative to wild-type

prostate gland epithelial hyperplasia ( J:54465 )

• adult heterozygotes exhibit progressive prostate epithelial hyperplasia of reduced severity relative to homozygotes

abnormal prostate gland physiology ( J:54465 )

• at 6 weeks, heterozygotes exhibit a 4.5-fold increase in epithelial cell proliferation in the anterior prostate relative to wild-type mice

• adult heterozygotes show a significant reduction or loss of major secretory proteins in ventral prostate secretions

neoplasm

preneoplasia ( J:54465 )

• at 1 year, the heterozygous anterior prostate shows epithelial hyperplasia and dysplasia along with a marked increase in proliferating cells, modeling a preneoplastic condition

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
prostate cancer		DOID:10283	OMIM:176807 OMIM:300147 OMIM:300704 OMIM:601518 OMIM:602759 OMIM:608656 OMIM:608658 OMIM:609299 OMIM:609558 OMIM:610321 OMIM:610997 OMIM:611100 OMIM:611868 OMIM:611928 OMIM:611955 OMIM:611958 OMIM:611959	J:54465

Allelic Composition	Nkx3-1^tm1Hha/Nkx3-1⁺
Genetic Background	involves: 129S4/SvJae * C57BL/6

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Nkx3-1^tm1Hha mutation (0 available); any Nkx3-1 mutation (34 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

reproductive system

abnormal prostate gland anterior lobe morphology ( J:63764 )

• at 10 months, heterozygotes exhibit dysplastic changes in the anterior prostate, although of reduced severity relative to homozygotes

prostate gland anterior lobe hyperplasia ( J:63764 )

• at 2 months, heterozygotes exhibit a normal ductal epithelium in the anterior prostate (AP) relative to wild-type mice; however, moderate AP hyperplasia is observed at 10 months

prostate gland dorsolateral lobe hyperplasia ( J:63764 )

• by 10 months, heterozygotes also exhibit epithelial hyperplasia in the dorsolateral prostate, although of reduced severity relative to homozygotes

• similar to homozygotes, no hyperplasia is observed in heterozygous ventral prostatic lobes

endocrine/exocrine glands

abnormal prostate gland anterior lobe morphology ( J:63764 )

• at 10 months, heterozygotes exhibit dysplastic changes in the anterior prostate, although of reduced severity relative to homozygotes

prostate gland anterior lobe hyperplasia ( J:63764 )

• at 2 months, heterozygotes exhibit a normal ductal epithelium in the anterior prostate (AP) relative to wild-type mice; however, moderate AP hyperplasia is observed at 10 months

prostate gland dorsolateral lobe hyperplasia ( J:63764 )

• by 10 months, heterozygotes also exhibit epithelial hyperplasia in the dorsolateral prostate, although of reduced severity relative to homozygotes

• similar to homozygotes, no hyperplasia is observed in heterozygous ventral prostatic lobes

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
prostate cancer		DOID:10283	OMIM:176807 OMIM:300147 OMIM:300704 OMIM:601518 OMIM:602759 OMIM:608656 OMIM:608658 OMIM:609299 OMIM:609558 OMIM:610321 OMIM:610997 OMIM:611100 OMIM:611868 OMIM:611928 OMIM:611955 OMIM:611958 OMIM:611959	J:63764

Allelic Composition	Nkx3-1^tm2Mms/Nkx3-1⁺
Genetic Background	involves: 129S6/SvEvTac * C57BL/6

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Nkx3-1^tm2Mms mutation (1 available); any Nkx3-1 mutation (34 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

reproductive system

reproductive system phenotype ( J:88802 )

N	• prostate budding is normal

Allelic Composition	Braf^tm1Mmcm/Braf^tm1Mmcm Nkx3-1^{tm4(cre/ERT2)Mms}/Nkx3-1⁺ Pten^tm1Hwu/Pten⁺
Genetic Background	involves: 129P2/OlaHsd * 129S4/SvJae * 129S6/SvEvTac * C57BL/6

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Braf^tm1Mmcm mutation (4 available); any Braf mutation (62 available)
Nkx3-1^{tm4(cre/ERT2)Mms} mutation (13 available); any Nkx3-1 mutation (34 available)
Pten^tm1Hwu mutation (17 available); any Pten mutation (86 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

mortality/aging

premature death ( J:191327 )

• mutants develop lethal prostate cancer 4 months after tamoxifen induction

neoplasm

increased prostate gland tumor incidence ( J:191327 )

• mutants develop lethal prostate cancer 4 months after tamoxifen induction

• tumors are large and highly proliferative and are primarily composed of luminal epithelial cells

• tamoxifen treated mutants do not display significant tumor regression at 2 weeks following castration, indicating that tumors are resistant to castration

• tumors from tamoxifen treated mutants show absence of cellular senescence and are highly proliferative

• treatment of tamoxifen treated mutants with a combination of rapamycin and PD0325901 (a mitogen-activated protein/extracellular signal-regulated kinase inhibitor) results in a reduction in tumor weight, growth, and proliferation

increased prostate gland adenocarcinoma incidence ( J:191327 )

• tamoxifen treated mutants develop invasive adenocarcinoma by 2-3 months after tamoxifen induction

increased prostate intraepithelial neoplasia incidence ( J:191327 )

• tamoxifen treated mutants display prostate intraepithelial neoplasia (PIN) by 2-4 weeks after tamoxifen induction

increased metastatic potential ( J:191327 )

• metastases to lungs and lymph nodes are seen in tamoxifen treated mutants and disseminated tumor cells are seen in the bone marrow

endocrine/exocrine glands

increased prostate gland tumor incidence ( J:191327 )

• mutants develop lethal prostate cancer 4 months after tamoxifen induction

• tumors are large and highly proliferative and are primarily composed of luminal epithelial cells

• tamoxifen treated mutants do not display significant tumor regression at 2 weeks following castration, indicating that tumors are resistant to castration

• tumors from tamoxifen treated mutants show absence of cellular senescence and are highly proliferative

increased prostate gland adenocarcinoma incidence ( J:191327 )

• tamoxifen treated mutants develop invasive adenocarcinoma by 2-3 months after tamoxifen induction

increased prostate intraepithelial neoplasia incidence ( J:191327 )

• tamoxifen treated mutants display prostate intraepithelial neoplasia (PIN) by 2-4 weeks after tamoxifen induction

reproductive system

increased prostate gland tumor incidence ( J:191327 )

• mutants develop lethal prostate cancer 4 months after tamoxifen induction

• tumors are large and highly proliferative and are primarily composed of luminal epithelial cells

• tamoxifen treated mutants do not display significant tumor regression at 2 weeks following castration, indicating that tumors are resistant to castration

• tumors from tamoxifen treated mutants show absence of cellular senescence and are highly proliferative

increased prostate gland adenocarcinoma incidence ( J:191327 )

• tamoxifen treated mutants develop invasive adenocarcinoma by 2-3 months after tamoxifen induction

increased prostate intraepithelial neoplasia incidence ( J:191327 )

• tamoxifen treated mutants display prostate intraepithelial neoplasia (PIN) by 2-4 weeks after tamoxifen induction

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
prostate cancer		DOID:10283	OMIM:176807 OMIM:300147 OMIM:300704 OMIM:601518 OMIM:602759 OMIM:608656 OMIM:608658 OMIM:609299 OMIM:609558 OMIM:610321 OMIM:610997 OMIM:611100 OMIM:611868 OMIM:611928 OMIM:611955 OMIM:611958 OMIM:611959	J:191327

Allelic Composition	Nkx3-1^{tm4(cre/ERT2)Mms}/Nkx3-1⁺ Pten^tm1Hwu/Pten^tm1Hwu
Genetic Background	involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Nkx3-1^{tm4(cre/ERT2)Mms} mutation (13 available); any Nkx3-1 mutation (34 available)
Pten^tm1Hwu mutation (17 available); any Pten mutation (86 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

neoplasm

increased prostate gland adenocarcinoma incidence ( J:153425 )

• castrated male mice show rapid formation of high-grade PIN and carcinoma after androgen-mediated prostate regeneration with evidence of microinvasion

increased prostate intraepithelial neoplasia incidence ( J:153425 , J:191327 )

• castrated male mice show rapid formation of high-grade PIN and carcinoma after androgen-mediated prostate regeneration with evidence of microinvasion (J:153425)

• mutants show extensive prostate intraepithelial neoplasia (PIN) III and PIN IV 9-12 months after tamoxifen induction, with some areas of squamous papilloma, however mutants rarely develop lethal prostate cancer up to 2 years following tamoxifen induction (J:191327)

reproductive system

increased prostate gland adenocarcinoma incidence ( J:153425 )

• castrated male mice show rapid formation of high-grade PIN and carcinoma after androgen-mediated prostate regeneration with evidence of microinvasion

increased prostate intraepithelial neoplasia incidence ( J:153425 , J:191327 )

• castrated male mice show rapid formation of high-grade PIN and carcinoma after androgen-mediated prostate regeneration with evidence of microinvasion (J:153425)

endocrine/exocrine glands

increased prostate gland adenocarcinoma incidence ( J:153425 )

• castrated male mice show rapid formation of high-grade PIN and carcinoma after androgen-mediated prostate regeneration with evidence of microinvasion

increased prostate intraepithelial neoplasia incidence ( J:153425 , J:191327 )

• castrated male mice show rapid formation of high-grade PIN and carcinoma after androgen-mediated prostate regeneration with evidence of microinvasion (J:153425)

Allelic Composition	Klf6^tm1Fjs/Klf6^tm1Fjs Nkx3-1^tm3(cre)Mms/Nkx3-1⁺
Genetic Background	involves: 129/Sv * C57BL/6

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Klf6^tm1Fjs mutation (0 available); any Klf6 mutation (15 available)
Nkx3-1^tm3(cre)Mms mutation (0 available); any Nkx3-1 mutation (34 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

Abnormality in ductal branching in the Klf6^tm1Fjs/Klf6^tm1Fjs Nkx3-1^tm3(cre)Mms/Nkx3-1⁺ prostate epithelium

endocrine/exocrine glands

abnormal prostate gland anterior lobe morphology ( J:153183 )

• lacks secondary branches

• epithelial infolding is significantly reduced resulting in a defined layer of epithelial cells outlining the main ducts

abnormal prostate gland branching morphogenesis ( J:153183 )

• impaired branching is seen in the anterior prostate in all males by P5

• at 6 months and 1 year of age most mature prostates still lack secondary branching in the anterior prostate

• branching defects are not as apparent in the dorsal and ventral prostates possibly as a result of less efficient Cre mediated recombination

abnormal prostate gland duct morphology ( J:153183 )

• in the dorsal and ventral prostates the luminal spaces of the ducts are increased

• in the anterior prostate, epithelial infolding is significantly reduced resulting in a defined layer of epithelial cells outlining the main ducts

reproductive system

abnormal prostate gland anterior lobe morphology ( J:153183 )

• lacks secondary branches

• epithelial infolding is significantly reduced resulting in a defined layer of epithelial cells outlining the main ducts

abnormal prostate gland branching morphogenesis ( J:153183 )

• impaired branching is seen in the anterior prostate in all males by P5

• at 6 months and 1 year of age most mature prostates still lack secondary branching in the anterior prostate

• branching defects are not as apparent in the dorsal and ventral prostates possibly as a result of less efficient Cre mediated recombination

abnormal prostate gland duct morphology ( J:153183 )

• in the dorsal and ventral prostates the luminal spaces of the ducts are increased

• in the anterior prostate, epithelial infolding is significantly reduced resulting in a defined layer of epithelial cells outlining the main ducts

Allelic Composition	Nkx3-1^tm1Mms/Nkx3-1⁺ Pten^tm1Rps/Pten⁺
Genetic Background	involves: 129S1/Sv * 129S1/SvImJ * C57BL/6J

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Nkx3-1^tm1Mms mutation (0 available); any Nkx3-1 mutation (34 available)
Pten^tm1Rps mutation (0 available); any Pten mutation (86 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

neoplasm

increased prostate gland tumor incidence ( J:75085 )

• early carcinoma lesions are seen in the prostate at 6 months of age

increased prostate intraepithelial neoplasia incidence ( J:75085 )

• at 6 months of age, high-grade prostatic intraepithelial neoplasia/early carcinoma lesions are seen in 36% of prostates, and by 12 months, all mice show lesions

• multifocal lesions in the prostate are comprised of poorly differentiated cells with prominent and multiple nucleoli, an increased nuclear/cytoplasmic ratio, and frequent mitotic figures

• lesions usually fill the affected prostatic ducts and are highly vascularized, show an increase in cytokeratins, an absence of basal epithelium, and a high proliferative index

• lesions show absence of Nkx3-1 protein expression, although mRNA is present and allelic loss of Pten

endocrine/exocrine glands

increased prostate gland tumor incidence ( J:75085 )

• early carcinoma lesions are seen in the prostate at 6 months of age

increased prostate intraepithelial neoplasia incidence ( J:75085 )

• at 6 months of age, high-grade prostatic intraepithelial neoplasia/early carcinoma lesions are seen in 36% of prostates, and by 12 months, all mice show lesions

• multifocal lesions in the prostate are comprised of poorly differentiated cells with prominent and multiple nucleoli, an increased nuclear/cytoplasmic ratio, and frequent mitotic figures

• lesions usually fill the affected prostatic ducts and are highly vascularized, show an increase in cytokeratins, an absence of basal epithelium, and a high proliferative index

• lesions show absence of Nkx3-1 protein expression, although mRNA is present and allelic loss of Pten

reproductive system

increased prostate gland tumor incidence ( J:75085 )

• early carcinoma lesions are seen in the prostate at 6 months of age

increased prostate intraepithelial neoplasia incidence ( J:75085 )

• at 6 months of age, high-grade prostatic intraepithelial neoplasia/early carcinoma lesions are seen in 36% of prostates, and by 12 months, all mice show lesions

• multifocal lesions in the prostate are comprised of poorly differentiated cells with prominent and multiple nucleoli, an increased nuclear/cytoplasmic ratio, and frequent mitotic figures

• lesions usually fill the affected prostatic ducts and are highly vascularized, show an increase in cytokeratins, an absence of basal epithelium, and a high proliferative index

• lesions show absence of Nkx3-1 protein expression, although mRNA is present and allelic loss of Pten

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
prostate cancer		DOID:10283	OMIM:176807 OMIM:300147 OMIM:300704 OMIM:601518 OMIM:602759 OMIM:608656 OMIM:608658 OMIM:609299 OMIM:609558 OMIM:610321 OMIM:610997 OMIM:611100 OMIM:611868 OMIM:611928 OMIM:611955 OMIM:611958 OMIM:611959	J:75085

Contributing Projects: Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support.	last database update 01/20/2026 MGI 6.24